METHODS AND SYSTEMS FOR TIME-GATED FLUORESCENT-BASED DETECTION
20200292457 ยท 2020-09-17
Inventors
- Arjang Hassibi (Santa Clara, CA, US)
- Arun Manickam (San Jose, CA, US)
- Rituraj Singh (Sunnyvale, CA, US)
- Robert G. Kuimelis (Palo Alto, CA, US)
Cpc classification
G01N21/6408
PHYSICS
G01J3/10
PHYSICS
G01N21/6486
PHYSICS
H04N25/771
ELECTRICITY
International classification
Abstract
The present disclosure provides methods, apparatus and systems for time-gated fluorescent-based detection. Time-based fluorescence analysis can be used in certain biochemical assays by measuring the emitted photon flux from fluorophores after an individual excitation pulse.
Claims
1. A device for detecting a presence or absence of an analyte in a solution, comprising: a chip comprising a sensor comprising an electronic shutter, wherein said sensor is configured to (i) collect a signal from said solution generated upon exposure of said solution to an excitation pulse within a first time period, (ii) with aid of said electronic shutter, remove photo-induced charge generated within a second time period in said sensor by said excitation pulse, wherein said second time period is different from said first time period, and (iii) subsequent to said photo-induced charge being removed, generate an output signal derived at least in part from said signal, wherein said output signal is indicative of said presence or absence of said analyte.
2. The device of claim 1, wherein said second time period precedes said first time period.
3. The device of claim 1, wherein said second time period is greater than duration of said excitation pulse.
4. The device of claim 1, wherein said chip comprises a plurality of individually addressable locations, wherein said sensor comprising said electronic shutter is disposed on a first location of said plurality of individually addressable locations; and wherein an additional sensor comprising an additional electronic shutter is disposed on an additional location of said plurality of individually addressable locations.
5. The device of claim 1, wherein said signal comprises an electrical signal, and wherein said sensor further comprises at least one transducer configured to convert an optical signal from said solution to said electrical signal.
6. The device of claim 5, wherein said electronic shutter comprises an electronic shutter switch operably coupled to said at least one transducer, which electronic shutter switch is configured to facilitate said removal of said photo-induced charge from said at least one transducer upon application of a voltage to said electronic shutter switch.
7. The device of claim 5, wherein said sensor further comprises at least one integrator configured to integrate said electrical signal.
8. The device of claim 7, wherein said sensor further comprises at least one integration switch disposed between and operably coupled to said at least one transducer and said at least one integrator, wherein said at least one integration switch is configured to transfer said electrical signal from said at least one transducer to said at least one integrator.
9. The device of claim 7, wherein said sensor further comprises at least one additional transducer operably coupled to said at least one integrator, which said at least one additional transducer is configured to convert said electrical signal integrated by said at least one integrator to said output signal.
10. The device of claim 1, wherein said signal comprises photo-induced charge, and wherein said output signal comprises voltage.
11. The device of claim 1, wherein said chip is included in a complementary metal oxide semiconductor (CMOS) integrated circuit (IC).
12. The device of claim 1, wherein said chip further comprises a biosensing layer adjacent to said sensor, and wherein said biosensing layer comprises at least one probe that specifically binds to said analyte.
13. The device of claim 12, wherein said signal is derived at least in part from an optical signal produced by a label associated with said analyte upon binding of said analyte to said at least one probe.
14. The device of claim 13, wherein said label is a fluorophore.
15. The device of claim 12, wherein said signal is derived at least in part from an optical signal or change thereof from said at least one probe or said analyte upon binding of said analyte to said at least one probe.
16. The device of claim 15, wherein said at least one probe comprises an energy donor and said analyte comprises an energy acceptor.
17. The device of claim 16, wherein said energy donor is a fluorophore, and wherein said energy acceptor is an additional fluorophore or a quencher.
18. The device of claim 12, wherein said biosensing layer comprises at least one control probe, and wherein said sensor is configured to collect a control signal from said at least one control probe and normalize said collected signal using said control signal.
19. The device of claim 18, wherein said at least one control probe does not bind to or interact with said analyte.
20. The device of claim 12, further comprising a reaction chamber, a controllable fluidic unit, a temperature control unit, and a digital unit.
21. The device of claim 20, wherein said reaction chamber is configured to interface said solution with said chip, and wherein said interfacing comprises an interaction between said analyte and said biosensing layer of said chip.
22. The device of claim 20, wherein said controllable fluidic unit is configured to transfer at least a portion of said solution into or out of said reaction chamber.
23. The device of claim 21, wherein said digital unit is configured to receive or store said output signal from said chip.
24. The device of claim 1, wherein said chip is configured to repeat (i)-(ii) multiple times prior to (iii).
25. The device of claim 24, wherein said output signal is a single output.
26. A method for detecting a presence or absence of an analyte in a solution, comprising: (a) activating a chip comprising a sensor comprising an electronic shutter, wherein said sensor is configured to (i) collect a signal generated upon exposure of said solution to an excitation pulse within a first time period, (ii) with aid of said electronic shutter, remove photo-induced charge generated within a second time period in said sensor by said excitation pulse, wherein said second time period is different from said first time period, and (iii) subsequent to said photo-induced charge being removed, generate an output signal derived at least in part from said signal, wherein said output signal is indicative of said presence or absence of said analyte; (b) removing said photo-induced charge generated within said second time period in said sensor by said excitation pulse, with aid of said electronic shutter; (c) collecting said signal generated upon exposure of said solution to said excitation pulse within said first time period; and (d) subsequent to said photo-induced charge being removed, generating said output signal derived at least in part from said signal, which output signal is indicative of said presence or absence of said analyte.
27. The method of claim 26, wherein said sensor is a time-gated fluorescence (TGF) photo sensor.
28. The method of claim 26, further comprising integrating said signal collected in (c) using said sensor.
29. The method of claim 26, further comprising, repeating (b)-(c) one or more times.
30. The method of claim 29, wherein said one or more times comprise greater than or equal to about 100 times.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also figure and FIG. herein), of which:
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
DETAILED DESCRIPTION
[0048] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
[0049] The term analyte or target as used herein generally refers to a molecular species to be detected. Examples include small molecules such as organic compounds, drugs, hormones, lipids, steroids, or metabolites; polynucleotides such as deoxyribonucleic acid (DNA) molecules, ribonucleic acid (RNA) molecules, and peptide nucleic acid (PNA); polypeptides such as proteins, peptides, antibodies, antigens, enzymes, and receptors; as well as tissues, organelles, and other receptor probes.
[0050] The term probe or capturing probe as used herein generally refers to a molecular species and/or other markers that can bind to a specific analyte or target. Probes can comprise molecules and can be bound to the substrate, molecules, or other solid surface, directly or via a linker. Non-limiting examples of linkers include amino acids, polypeptides, nucleotides, oligonucleotides, and chemical linkers. A plurality of probes can be immobilized to a substrate, molecule or other solid surface and can be referred to as a probe array. A plurality of probes of a probe array may be arranged uniformly, for example as an arrangement of spots, or non-uniformly.
[0051] The term about or nearly as used herein generally refers to within +/15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the designated amount.
[0052] The term label as used herein refers to a molecular structure that can be attached to a molecule (e.g., a target and/or a probe), to make the molecule detectable, distinguishable and/or traceable by providing a characteristic which may not be intrinsic to the target molecule. Examples of labels may include are luminescent molecules (e.g., fluorophores), reduction-oxidation (redox) species, or enzymes. In some cases, labels may comprise fluorophores with long lifetimes, such as, for example, lanthanide chelates and transition metal chelates, which are luminescent or phosphorescent.
[0053] The term nucleotide, as used herein, generally refers a molecule that can serve as the monomer, or subunit, of a nucleic acid, such as deoxyribonucleic acid (DNA) or ribonucleic acid RNA). A nucleotide can be a deoxynucleotide triphosphate (dNTP) or an analog thereof, e.g., a molecule having a plurality of phosphates in a phosphate chain, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 phosphates. A nucleotide can generally include adenosine (A), cytosine (C), guanine (G), thymine (T) and uracil (U), or variants thereof. A nucleotide can include any subunit that can be incorporated into a growing nucleic acid strand. Such subunit can be an A, C, G, T, or U, or any other subunit that is specific to one or more complementary A, C, G, T or U, or complementary to a purine (i.e., A or G, or variant thereof) or a pyrimidine (i.e., C, T or U, or variant thereof). A subunit can enable individual nucleic acid bases or groups of bases (e.g., AA, TA, AT, GC, CG, CT, TC, GT, TG, AC, CA, or uracil-counterparts thereof) to be resolved. A nucleotide may be labeled or unlabeled. A labeled nucleotide may yield a detectable signal, such as an optical, electrostatic or electrochemical signal.
[0054] As used herein, the terms polynucleotide, oligonucleotide, nucleotide, nucleic acid and nucleic acid molecule generally refer to a polymeric form of nucleotides (polynucleotides) of various lengths, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). Examples of nucleotide sequences are sequences corresponding to natural or synthetic RNA or DNA including genomic DNA and messenger RNA. The length of the sequence can be any length that can be amplified into nucleic acid amplification products, or amplicons, for example, up to about 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 1,000, 1,200, 1,500, 2,000, 5,000, 10,000 or more than 10,000 nucleotides in length, or at least about 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 1,000, 1,200, 1,500, 2,000, 5,000, 10,000 or 10,000 nucleotides in length.
[0055] As used herein, the terms peptide, polypeptide, and protein are used interchangeably, and generally refer to a compound comprised of amino acid residues covalently linked by peptide bonds. Polypeptides may include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. Examples of polypeptides may include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptides and variants thereof, modified polypeptides, derivatives, analogs, fusion proteins, or combinations thereof. A polypeptide may be a natural peptide, a recombinant peptide, or a combination thereof.
[0056] As used herein, the singular forms a, an, and the include plural references unless the context clearly dictates otherwise.
[0057] The term detector as used herein generally refers to a device, generally including optical and/or electronic components that can detect signals.
TGF System Overview
[0058] The present disclosure provides methods, devices, reagents and systems based on time-gated fluorescence (TGF). The system may comprise a TGF based biochip. The TGF biochip may be semiconductor-integrated. In some cases, the semiconductor platform and manufacturing process through which the system is created is complementary metal-oxide-semiconductor (CMOS).
[0059] The methods and systems of the present disclosure may be used to detect, analyze, and/or quantify a plurality of analytes present in an aqueous sample through TGF transduction methods. The TGF CMOS biochip can be a monolithically-integrated biosensor array with addressable locations. See, e.g., U.S. Pat. Nos. 9,708,647, 9,499,861 and 10,174,367, each of which is entirely incorporated herein by reference. Each addressable location may comprise an independently operating TGF photo-sensor that detects TGF signals from its dedicated sensing area. The sensing/detection may be conducted in real-time and in the presence of an aqueous sample, or when such a sample is washed away. The TGF photo-sensor can adopt periodic charge integration (PCI) methods in which periodical signal accumulation is performed by applying multiple time-gated excitation pulses. The TGF CMOS biochip system can physically interface with the aqueous sample and apply physiochemical processes to the sample, including, for example, applying time-varying temperature profiles, biochemical reagents, or pulsed excitation photon fluxes to the sample.
[0060] The TGF CMOS biochip system, as illustrated in
TGF CMOS Biochip
[0068] As shown in
CMOS Integrated Circuits (IC)
[0074] The architecture of the integrated CMOS IC for the TGF biochip is illustrated in
[0075] The chip may also include a resistive heater and a temperature sensor to accommodate the temperature control of the reaction chamber (e.g., Hassibi, A. et al. A fully integrated CMOS fluorescence biochip for DNA and RNA testing, IEEE Journal of Solid-State Circuits, 52(11):2857-2870, 2017). In addition, the CMOS IC can also include a control block to be programmed and accessed off-chip by the user to set the functionality of the chip and manage the data acquisition.
[0076] The general topology of an example TGF pixel is shown in
[0077] TGF pixel of the present disclosure may be different from conventional detectors for TGF or time-resolved fluorescence. One difference is the absence of the S.sub.S and S.sub.I and the capability of selectively discarding or integrating the generated charge of the PCT. In
[0081] In the present disclosure, by using the topology shown in
[0085] The challenges in the implementation of PCI-TGF may revolve around the circuit and device implementation of the switches, efficient approaches of transferring charge in time intervals compatible with TGF, and CIE.
Biosensing Layer
[0086] The biosensing layer as provided herein may include an organic layer that may be created on top of a CMOS IC and interfacing the reaction chamber to: (a) form addressable location(s) for probes on top of the pixels; and (b) enable TGF transduction by first capturing targets and subsequently creating TGF signals as a function of the probe target interactions and/or structure of the captured target.
[0087] Biosensing layers may be created by various methods. For example, specific probe structures may be physically printed, immobilized, or spotted or chemically synthesized on a surface. In some cases, probes are first randomly distributed within the array 2D surface and then identified prior to detecting the targets by alternative approaches that are known in the field. In some cases, the surface of the IC (typically made of SiO.sub.2 or Si.sub.3N.sub.4) may be chemically modified with linkers and/or thin film structures to become compatible with probe attachment.
[0088]
Reaction Chamber
[0089] The reaction chamber as provided herein may be a fluidic chamber that interfaces with the CMOS TGF biochip and contains the fluidic sample with analytes, targets, and other biochemical reagents that are required for the execution of the TGF assay.
[0090] The volume of this reaction chamber can be between about 0.1 L to 10,000 L, e.g., between about 1 L to 100 L.
[0091] The reaction chamber may comprise a plurality of inlets and outlets to accommodate the interfacing with the controllable fluidic system to insert or remove fluids.
[0092] To accommodate TGF, the fluidic system can provide a transparent optical travel path for the pulse F to go through the fluidic and reach the biosensing layer. The transmittance in the wavelengths of F.sub.x can be from 1% to 99.9%, but typically is from 5% to 80%.
[0093] The reaction chamber can be built using a variety of materials such as polymers, glass, semiconductor, crystals, or ceramics materials, or a combination of them.
Excitation Source
[0094] The excitation source as provided herein may comprise an optical light source that can create a wavelength selective photon flux (F.sub.x) with a controllable and time-varying amplitude. The light source may illuminate the biosensing layer of the system and the coordinates in which TGF transduction takes place.
[0095] The excitation source center wavelength can be anywhere between about 200 nm to 1500 nm, e.g., between about 300 nm to 800 nm.
[0096] The excitation source spectral span (bandwidth) may be from about 1 nm to 500 nm, e.g., from about 10 nm to 100 nm.
[0097] The excitation source photon flux may be directional and may be optically collimated.
[0098] The excitation source peak output power may be from about 10 mW to 100 W, e.g., from about 100 mW to 10 W.
[0099] The excitation source power may be controllable and modulated with bandwidth of up to about 1 GHz, e.g., up to about 1 MHz
[0100] The excitation source turns off and on times may be as fast as about 0.1 nanosecond (ns), e.g., as fast as about 1 microsecond (s).
Controllable Fluidic System
[0101] The controllable fluidic system introduces into, and/or removes from, and/or confines within the reaction chamber aqueous media that can include samples and assay reagents, and/or TGF transduction reagents in a controlled fashion by the user. The workflow and sequence of each fluidic operation may be defined by the assaying method and can be, for example, flow-through and mono-directional, or closed-tube.
[0102] The controllable fluidic system may use fluidic components such as pumps, valves, and tubing to perform the workflow.
Temperature Controller
[0103] The temperature controller system can establish a specific temperature for the fluidic of the reaction chamber, and/or create a temperature profile that requires heating and/or cooling. A temperature controller can include a feedback control system that measures the temperature, using temperature sensors within the CMOS biochip IC and/or sensor devices coupled with the reaction chamber (such as a thermistor or a thermocouple), and, based on the measured temperature, add or remove heat from the reaction chamber using CMOS biochip IC heaters and/or thermal devices (such as Peltier devices or resistive heaters). Temperature controllers can comprise heat sinks for removing heat. Temperature controllers can have components within the CMOS IC, including resistive heaters and/or temperature sensors.
[0104] Temperature controllers can change the temperature of a substrate, reaction chamber, or array pixel. The rate of temperature change can be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 C./minute. The rate of temperature change can be at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 C./minute. The rate of temperature change can be at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 C./minute. Temperature controllers can change temperature at a linear rate (e.g., 5 C./second). Alternatively, temperature controllers can change temperature at a non-linear rate. Temperature controllers can increase or decrease temperature.
Digital System
[0105] The digital system is essentially a computing and controlling digital hardware And embedded software than can control and coordinate the functionality of the components of the system.
TGF Reagents and Reporter Molecular Constructs
[0106] To enable TGF transduction, we can use molecular structures and constructs that exhibit fluorescence activity. Such molecular structures are sometimes referred to as fluorophores (or fluorochromes, similarly to chromophores) which are chemical compound that can re-emit light upon light excitation with life-times from about 10 ps to 10 ms, e.g., from about 1 ns to 100 ns.
[0107] As provided herein, various types of fluorophores can be adopted by a TGF system. In some cases, fluorophores that have longer life-times, e.g., greater than about 100 ns, may be used. In cases where fluorophores with longer lifetime are used: [0108] Longer life-time fluorophores may require lower speed PCI-TGF systems in the CMOS Biochip IC; [0109] The excitation source switching speed can be more manageable, and more cost-efficient light sources can be used; and [0110] The negative effects of background autofluorescence from the biological sample and/or materials in the fluidic chamber and/or biolayer may be mitigated, if the they have shorter life-time compared to the adopted TGF fluorophore.
[0111] TGF systems may not need an excitation and emission filter set, or other filters of wavelength to transmit a desired signal for an analyte and/or remove background fluorescence from signals of the analyte. In some cases, the emission filter may filter out violet, blue, green, yellow, orange, and red light, or any combination thereof.
[0112] Various types of fluorophores may permit multi-color capabilities. In TGF, differentiating fluorophores may be determined by the differences in their fluorescence lifetimes after excitation. In some cases, these fluorophores can be reactive and/or conjugated dyes, nucleic acid dyes, fluorescent proteins, and cell function dyes. Once emission light is pulsed in the direction of a substrate containing the fluorophore species, a shutter may close off the detection apparatus from the emission light and the reflected emission light. The shutter may be removed to let in the desired fluorescent light. A first fluorophore with a shorter lifetime can be detected among the detected signals if the shutter opens shortly after the emission is stopped. A second fluorophore with a longer lifetime can be detected if the shutter is opened after waiting for a longer time after the emission is stopped. In this scenario, the second fluorophore (longer lifetime) may be detected with little or no interference of the first fluorophore (shorter lifetime). In addition, readings of the signals corresponding to the first fluorophore (shorter lifetime) in the presence of the second fluorophore (longer lifetime) can be estimated or calculated by calibration of the detected signals using information about the second fluorophore (longer lifetime) detected and/or determined later. Other experimental designs for the multiplex detection of multiple fluorophores are possible with or without the use of emission and excitation filter sets. Accordingly, multiple fluorophores can be detected in a single experiment by the opening and closing of the shutter following the emission in the absence of excitation and emission filter sets. Individual species of fluorophores can be detected based on the differences in their decay rates by varying the delay profiles of the shutter and the time during which the shutter is opened. The multi-color capability may be limited by shutter speed and the overlap between fluorescence decay rates of the fluorophores to be detected.
[0113] For example, in some examples, metal chelate, such as Lanthanide chelates can be used as TGF fluorophores. In some cases, TGF fluorophores may predominantly act as molecular reporters in TGF assays either as a standalone reporter or an element (donor or acceptor) in a fluorescence energy transfer moiety. Examples include, but are not limited to, Forster Resonance Energy Transfer (FRET) technologies. See Song, Y., et al., Development of FRET assay into quantitative and high-throughput screening technology platforms for protein-protein interactions, Annals of biomedical engineering 39(4): 1224-1234, 2011. The role of TGF fluorophores may include facilitating the generation of a specific TGF signal that may be correlated to the presence or absence of a molecular reaction or presence or absence of a specific target molecule.
[0114] TGF fluorophores can be used as labels for specific target analytes, in applications where the targets can be chemically modified to incorporate a TGF fluorophore. Examples includes, but are not limited to, Northern blots, Southern blots, DNA microarrays, quantitative Polymerase Chain Reaction (PCR), digital PCR, and diagnostic assays. [0115] In microarrays and Northern blots, the mRNA target analyte may be converted into a fluorophore-labelled complementary DNA (cDNA), for example, through reverse transcription. [0116] In Southern blots, a fluorophore-labeled cDNA may be used to identify a target sequence. [0117] In quantitative polymerase chain reaction (PCR) and digital PCR (dPCR), the fluorophore may be incorporated into an amplified nucleic acid sequence or a primer sequence to demonstrate the accumulation of a target sequence (See, e.g., Y. Wong et al., Applications of digital PCR in precision medicine, Expert Review of Precision Medicine and Drug Development 2(3):177-186, 2017). [0118] In a diagnostic assay, a device may be used to sequester target nucleic acids, and a fluorophore-labelled cDNA may be used for direct detection.
[0119] TGF fluorophores can also be used as labels for the detection of probes in sandwich assays. Examples include, but are not limited to, Western Blots, Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immuno SPOT (ELISPOT) including FluoroSpot (See, e.g., G. Kesa et al., Comparison of ELISpot and FluoroSpot in the Analysis of Swine Flu-Specific IgG and IgA Secretion by in Vivo Activated Human B Cells, Cells 1(2): 27-34, 2012), and protein arrays. [0120] In these methods, the TGF fluorophores may be used as a direct method for detection, in which the fluorophore is conjugated to the primary detection antibody. [0121] In these methods, the TGF fluorophore may also be used as an indirect method for detection, in which the fluorophore is conjugated to a secondary antibody. [0122] ELISPOT is a type of assay that quantitatively measures the frequency of cytokine secretion for a single cell. The ELISPOT Assay is also a form of immunostaining that uses antibodies to detect an analyte, including but not limited to, any biological or chemical substance being identified or measured, such as, for example, protein analyte. [0123] The FluoroSpot Assay is a variation of the ELISpot assay. The FluoroSpot Assay uses fluorescence to analyze multiple analytes. It can detect the secretion of more than one type of protein or other analytes.
[0124] TGF fluorophores can be used as labels in cell sorting, counting, and detecting methods. An example may be flow cytometry, in which cells are labeled with a fluorophore. [0125] In this method, the cells may be sorted and counted by their fluorescence profiles. [0126] In this method, the specific cellular characteristics and/or functions may be identified by their fluorescence profiles.
[0127] TGF fluorophores can be used in applications where solid-phase and immobilized probes are labeled. Examples are inverse fluorophore assays (e.g., A. Hassibi et al., Multiplexed identification, quantification and genotyping of infectious agents using a semiconductor biochip, Nature biotechnology, 36(8):738-745, 2018)
[0128] TGF fluorophores can be used in assays in which the chemical reactions are monitored while a target molecule is introduced to a reacting reagent. The target molecule and/or the reacting reagent may include TGF fluorophores. Examples are Sanger sequencing, Next Generation Sequencing (NGS) assays such as sequence-by-synthesis (SBS) (See, Ansorge; Metzker; and Pareek et al., Sequencing technologies and genome sequencing, J. Appl. Genet., 52(4):413-435, 2011), sequence-by-hybridization (SBH) (See, Qin, Schneider and Brenner, Sequencing by Hybridization of Long Targets, PLoS One., 7(5):e35819, 2012), and pyrosequencing. [0129] In this method, Single Molecule Real Time (SMRT) sequencing and Illumina sequencing can use TGF fluorophore-labeled nucleotides to determine the sequence of a nucleic acid
[0130] Sequence information of nucleic acids may be used to improve people's lives. (See, e.g., Ansorge, W., Next-generation DNA sequencing techniques, New Biotech. 25(4):195-203, 2009). Several DNA sequencing platforms have been commercially available. The availability of parallel NGS technologies may enable the comprehensive analysis for biological targets, including but not limited to genomes, transcriptomes and interactomes. (See, e.g., Shendure, J. and Ji, H., Next-generation DNA sequencing, Nature Biotech. 26:1135-45, 2008). However, although NGS technologies may produce comprehensive results, their turnaround time may be too slow to address the rapid progression of an infectious process in critically ill patients. In addition, while multiplexing a large number of target amplification reactions (e.g., multiplexed PCR) may be possible, but it is not straightforward to detect multiple amplicons simultaneously.
[0131] Commercially available NGS sequencing platforms may include the Illumina Genome Analyzer, the Roche (454) Genome Sequencer, the Life Technologies SOLiD platform, and real-time sequencers such as those from Pacific Biosciences. These platforms may require the construction of a set of DNA fragments from a biological sample. In most cases, the DNA fragments are flanked by platform-specific adapters.
Example 1
[0132] In this example, a fully-integrated TGF CMOS biochip is presented that is specifically designed for DNA and protein addressable arrays of biotechnology. As shown in
[0133] The architecture of the chip and 120 m-pitch biosensing pixels and decimation cells are shown in
[0134] In the CWF mode (i.e., no pulsed excitation source or electronic shuttering), the current detector operates continuously with frequency of f.sub.c while the decimation cell implements a sinc.sup.2 filter, by performing a two-stage 32-bit accumulation followed by down-sampling and readout with frequency of f.sub.s. In the TGF mode, similar operation is done, but with the exception of periodic activation of an electronic shutter capable of diverting I.sub.ph from the integrator. This operation blocks the optical excitation pulses and reduces the natural autofluorescence background from biological media that typically have lifetimes <50 ns. The chip then accumulates and measures the fluorescence emissions at pre-programmed time intervals.
[0135] In this chip, the TGF pixels, the decimation arrays, bandgap temperature sensor, and reference voltage DACs are all operated and read by a single digital core block operating at 50 MHz and is accessible through a serial peripheral interface (SPI) port (
[0136] In
[0137] The decimation array has a dedicated bit cell for every pixel. The bit cell consists of a 32-bit incrementor, followed by a 32-bit adder, forming the two-stage accumulation unit (
[0138] The electrical and optical measurements for this biochip are reported in
[0139] In
[0140] In
Example 2
[0141] This example shows how PCI-TGF pixels can be designed in applications where high-density biosensor pixels arrays are required, such as DNA SBS and DNA SBH systems. The example also shows how miniaturized PCI-TGF pixels can be incorporated into standard high-density image sensor arrays. As the example shows, PCI can be added into the circuitry of multi-million pixel CMOS image sensors that can have sub-micron pixel dimensions.
[0142]
[0143] In
[0144] In
[0145] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.